LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

Search

TG Therapeutics Inc

Gesloten

SectorGezondheidszorg

32.14 -0.65

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

31.85

Max

32.55

Belangrijke statistieken

By Trading Economics

Inkomsten

23M

28M

Verkoop

20M

141M

K/W

Sectorgemiddelde

85.211

35.664

Winstmarge

19.97

Werknemers

370

EBITDA

25M

38M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+0.65% upside

Dividenden

By Dow Jones

Volgende Winsten

3 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

578M

5.1B

Vorige openingsprijs

32.79

Vorige sluitingsprijs

32.14

Nieuwssentiment

By Acuity

30%

70%

102 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

TG Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 sep 2025, 22:41 UTC

Belangrijke Marktbewegers

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12 sep 2025, 16:04 UTC

Belangrijke Marktbewegers

Upexi Shares Climb on Solana Gains

12 sep 2025, 15:03 UTC

Belangrijke Marktbewegers

Allied Gaming & Entertainment Shares Surge Following Crypto Investments

12 sep 2025, 20:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

12 sep 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 sep 2025, 20:09 UTC

Winsten

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12 sep 2025, 19:23 UTC

Marktinformatie

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sep 2025, 19:16 UTC

Marktinformatie

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sep 2025, 19:03 UTC

Marktinformatie

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12 sep 2025, 18:59 UTC

Marktinformatie

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12 sep 2025, 18:38 UTC

Marktinformatie
Winsten

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12 sep 2025, 18:33 UTC

Marktinformatie

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12 sep 2025, 18:22 UTC

Marktinformatie

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12 sep 2025, 16:56 UTC

Marktinformatie

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12 sep 2025, 16:22 UTC

Winsten

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12 sep 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 sep 2025, 16:19 UTC

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 sep 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

12 sep 2025, 16:11 UTC

Winsten

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12 sep 2025, 15:37 UTC

Marktinformatie

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12 sep 2025, 15:22 UTC

Marktinformatie

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12 sep 2025, 15:07 UTC

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 sep 2025, 14:34 UTC

Marktinformatie

Russia Sanctions Put Bid Back in Oil -- Market Talk

12 sep 2025, 14:10 UTC

Marktinformatie

Inflation Report Unlikely to Dissuade Canada From Rate Cut -- Market Talk

12 sep 2025, 13:58 UTC

Marktinformatie

Dollar Could Rise if Fed Sounds Cautious on Rate Cuts -- Market Talk

12 sep 2025, 13:58 UTC

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Super Micro, Adobe, Microsoft, Figure Technology, and More -- Barrons.com

12 sep 2025, 13:57 UTC

Winsten

AbbVie Stock Hit a Record on 'Big Win' for Blockbuster Drug. The Case for Buying In. -- Barrons.com

12 sep 2025, 13:56 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

12 sep 2025, 13:56 UTC

Marktinformatie

Canadian Dollar Faces Further Weakness Vs Non-U.S. Dollar Currencies -- Market Talk

12 sep 2025, 13:54 UTC

Marktinformatie

U.S. Natural Gas Recovers Ground -- Market Talk

Peer Vergelijking

Prijswijziging

TG Therapeutics Inc Prognose

Koersdoel

By TipRanks

0.65% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 32.67 USD  0.65%

Hoogste 50 USD

Laagste 11 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor TG Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

3 ratings

1

Buy

1

Hold

1

Sell

Technische score

By Trading Central

N/A / 34.86Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

102 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
help-icon Live chat